1. Dear Drugs-Forum readers: We are a small non-profit that runs one of the most read drug information & addiction help websites in the world. We serve over 4 million readers per month, and have costs like all popular websites: servers, hosting, licenses and software. To protect our independence we do not run ads. We take no government funds. We run on donations which average $25. If everyone reading this would donate $5 then this fund raiser would be done in an hour. If Drugs-Forum is useful to you, take one minute to keep it online another year by donating whatever you can today. Donations are currently not sufficient to pay our bills and keep the site up. Your help is most welcome. Thank you.

DEA to reschedule hydrocodone combination products tomorrow.

By desert flower, Aug 29, 2014 | Updated: Aug 30, 2014 | |
  1. desert flower
    The U.S. Drug Enforcement Administration (DEA) announced it will publish the Final Rule moving hydrocodone combination products (HCPs) from Schedule III to Schedule II tomorrow in the Federal Register. This Rule follows the recommendation by the Assistant Secretary for Health of the U.S. Department of Health and Human Services (HHS) and is supported by the DEA's own evaluation of clinical data.

    The DEA initially received a petition requesting that HCPs be reclassified as Schedule II of the Controlled Substances Act. In 2004, the DEA requested the HHS to provide scientific and medical evaluation of available data and a scheduling recommendation for HCPs. In 2008, the HHS recommended that HCPs remain controlled as a Schedule III drug. However, in 2009, the DEA requested that the data be reevaluated and another scientific and medical evaluation be provided. In December of 2013, the HHS submitted the reevaluation and their recommendation to place HCPs in Schedule II. The final conclusion to shift HCPs into Schedule II were based on the following findings: HCPs have a high potential for abuse (comparable to the Schedule II substance oxycodone), HCPs have a currently accepted medical use in treatment in the United States, and the abuse of HCPs may lead to severe psychological or physical dependence.

    This issuance affects all persons who handle (eg, manufacture, distribute, dispense, import, export, engage in research, conduct instructional activities with, conduct chemical analysis with, or possess) or propose to handle HCPs. This Final Rule will go into effect in 45 days.

    For more information visit FederalRegister.gov.



To make a comment simply sign up and become a member!